IGC (IGC Pharma) Shiller PE Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IGC IGC Pharma Inc IGC
29 GF Score
Price $0.27
GF Value $0.23
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


IGC Pharma  (AMEX:IGC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


IGC Pharma Shiller PE Ratio Related Terms


IGC Pharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for IGC Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Shiller PE Ratio Chart

IGC Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IGC Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IGC vs ATNM, NNVC, KYNB: Shiller PE Ratio Comparison

For the Biotechnology subindustry, IGC Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Shiller PE Ratio falls into.


IGC
29GF Score
IGC Pharma Inc IGC
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

IGC Pharma's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, IGC Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.0293/333.9520*333.9520
=-0.029

Current CPI (Jun. 2026) = 333.9520.

IGC Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201512 -0.020 236.525 -0.028
201603 -0.080 238.132 -0.112
201606 -0.020 241.018 -0.028
201609 -0.020 241.428 -0.028
201612 -0.004 241.432 -0.006
201703 -0.030 243.801 -0.041
201706 -0.020 244.955 -0.027
201709 -0.010 246.819 -0.014
201712 -0.019 246.524 -0.026
201803 -0.020 249.554 -0.027
201806 -0.020 251.989 -0.027
201809 -0.030 252.439 -0.040
201812 -0.029 251.233 -0.039
201903 -0.040 254.202 -0.053
201906 -0.035 256.143 -0.046
201909 -0.030 256.759 -0.039
201912 -0.041 256.974 -0.053
202003 -0.080 258.115 -0.104
202006 -0.047 257.797 -0.061
202009 -0.040 260.280 -0.052
202012 -0.056 260.474 -0.072
202103 -0.067 264.877 -0.084
202106 -0.037 271.696 -0.046
202109 -0.087 274.310 -0.106
202112 -0.047 278.802 -0.056
202203 -0.127 287.504 -0.148
202206 -0.054 296.311 -0.061
202209 -0.047 296.808 -0.053
202212 -0.042 296.797 -0.048
202303 -0.076 301.836 -0.084
202306 -0.039 305.109 -0.043
202309 -0.045 307.789 -0.049
202312 -0.088 306.746 -0.095
202403 -0.044 312.332 -0.047
202503 -0.016 319.799 -0.016
202506 -0.019 322.561 -0.020
202509 -0.020 324.800 -0.021
202512 -0.008 324.054 -0.008
202603 -0.025 330.213 -0.025
202606 -0.029 333.952 -0.029

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.27 is trading 18.3% above its estimated GF Value™ of $0.23. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • Shiller PE Ratio:
  • GF Value™: $0.23 vs. price of $0.27 (18.3% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price
$0.23
GF Value